BioStem Technologies, Inc. (BSEM) FinancialsBSEMFinancialBioStem Technologies, Inc.

BioStem Technologies, Inc. (BSEM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Hospital, accounting for 87.4% of total sales, equivalent to $5.36M. Another important revenue stream is Physician office. Understanding this composition is critical for investors evaluating how BSEM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, BioStem Technologies, Inc. maintains a gross margin of 52.55%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -106.35%, while the net margin is -113.57%. These profitability ratios, combined with a Return on Equity (ROE) of -74.74%, provide a clear picture of how effectively BSEM converts its operational activities into shareholder value.

In the context of the broader market, BSEM competes directly with industry leaders such as HRTX and BOLD. With a market capitalization of $63.01M, it holds a significant position in the sector. When comparing efficiency, BSEM's gross margin of 52.55% stands against HRTX's 69.28% and BOLD's N/A. Such benchmarking helps identify whether BioStem Technologies, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a 29% revenue growth in Q2 2026, reaching $7.9 million, which is a positive indicator of demand for its products. However, net income has been negative for the last two quarters, raising concerns about profitability.